Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · IEX Real-Time Price · USD
21.53
-0.30 (-1.37%)
At close: Apr 23, 2024, 4:00 PM
21.74
+0.21 (0.98%)
Pre-market: Apr 24, 2024, 4:56 AM EDT
Intellia Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for NTLA stock have an average target of 67.64, with a low estimate of 29 and a high estimate of 107. The average target predicts an increase of 214.17% from the current stock price of 21.53.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for NTLA stock from 15 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 | 4 | 3 |
| Buy | 12 | 12 | 12 | 10 | 10 | 8 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 21 | 21 | 18 | 18 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Hold Reiterates $29 | Hold | Reiterates | $29 | +34.70% | Apr 23, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy → Hold Downgrades $32 | Strong Buy → Hold | Downgrades | $32 | +48.63% | Feb 23, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $72 → $73 | Strong Buy | Maintains | $72 → $73 | +239.06% | Feb 23, 2024 |
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Feb 15, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $80 → $70 | Buy | Maintains | $80 → $70 | +225.13% | Nov 13, 2023 |
Financial Forecast
Revenue This Year
51.73M
from 36.28M
Increased by 42.61%
Revenue Next Year
55.83M
from 51.73M
Increased by 7.92%
EPS This Year
-5.73
from -5.42
EPS Next Year
-5.60
from -5.73
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 107.6M | 220.5M | 229.6M | 2.5B | 7.1B |
| Avg | 51.7M | 55.8M | 111.9M | 704.4M | 1.8B |
| Low | 8.8M | n/a | 19.6M | 49.0M | 298.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 196.7% | 326.3% | 311.2% | 2,164.6% | 907.7% |
| Avg | 42.6% | 7.9% | 100.4% | 529.7% | 159.4% |
| Low | -75.7% | - | -64.9% | -56.2% | -57.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.78 | -1.81 | -2.90 | 15.14 | 42.81 |
| Avg | -5.73 | -5.60 | -5.99 | -1.16 | 7.07 |
| Low | -6.93 | -7.44 | -9.40 | -7.83 | -4.08 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.